Background
Methods
Variable | number | % | |
---|---|---|---|
Age (years) | < 50 | 454 | 34.2% |
≥50 | 874 | 65.8% | |
Tumour size (mm) | < 20 | 646 | 48.7% |
≥20 | 681 | 51.3% | |
Nodal stage | 1 | 810 | 60.8% |
2 | 406 | 30.5% | |
3 | 111 | 8.3% | |
Grade | 1 | 202 | 15.2% |
2 | 459 | 34.5% | |
3 | 666 | 50.2% | |
ER status | negative | 314 | 23.8% |
positive | 1005 | 76.2% | |
HER2 status | negative | 1102 | 86.7% |
positive | 169 | 13.3% | |
Vascular invasion | negative | 733 | 55.0% |
suspected (probable) | 153 | 11.5% | |
positive (definite) | 435 | 32.7% | |
Distant metastasis | negative | 826 | 62.5% |
positive | 496 | 37.5% |
Immunohistochemistry
IHC scoring and statistical analysis
Results
Expression of pan-P38 and phosphorylated (p)-P38
Association of P38 with clinicopathological variables and disease biomarkers
Variable | pan-P38 | nuclear p-P38 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Negative/low | Positive/high |
p
| Negative/low | Positive/high |
p
| ||||||
Age | < 50 yrs | 187 | 57.9% | 136 | 42.1% | 0.258 | 318 | 70.0% | 136 | 30.0% | 0.751 |
≥50 yrs | 363 | 61.7% | 225 | 38.3% | 620 | 70.9% | 254 | 29.1% | |||
Size | < 20 mm | 232 | 56.2% | 181 | 43.8% |
0.025
*
| 421 | 65.2% | 225 | 34.8% |
< 0.001
*
|
≥20 mm | 316 | 63.7% | 180 | 36.3% | 516 | 75.8% | 165 | 24.2% | |||
Stage | 1 | 334 | 60.5% | 218 | 39.5% | 0.890 | 550 | 67.9% | 260 | 32.1% |
0.007
*
|
2–3 | 214 | 59.9% | 143 | 40.1% | 387 | 74.9% | 130 | 25.1% | |||
Grade | 1–2 | 237 | 55.4% | 191 | 44.6% |
0.004
*
| 413 | 62.5% | 248 | 37.5% |
< 0.001
*
|
3 | 311 | 64.7% | 170 | 35.3% | 524 | 78.7% | 142 | 21.3% | |||
NPI | good / medium | 440 | 58.9% | 307 | 41.1% | 0.095 | 760 | 68.8% | 344 | 31.2% |
0.002
*
|
Poor | 109 | 66.1% | 56 | 33.9% | 179 | 79.2% | 47 | 20.8% | |||
VI | negative or suspected | 354 | 59.9% | 237 | 40.1% | 0.722 | 602 | 67.9% | 284 | 32.1% |
0.002
*
|
positive (definite) | 192 | 61.1% | 122 | 38.9% | 331 | 76.1% | 104 | 23.9% | |||
ER | Negative | 167 | 74.6% | 57 | 25.4% |
< 0.001
*
| 244 | 77.7% | 70 | 22.3% |
< 0.001
*
|
Positive | 379 | 55.3% | 306 | 44.7% | 690 | 68.7% | 315 | 31.3% | |||
PR | Negative | 265 | 72.4% | 101 | 27.6% |
< 0.001
*
| 398 | 76.5% | 122 | 23.5% |
< 0.001
*
|
Positive | 264 | 51.4% | 250 | 48.6% | 507 | 67.3% | 246 | 32.7% | |||
HER2 | Negative | 463 | 60.5% | 302 | 39.5% | 1.000 | 775 | 70.3% | 327 | 29.7% | 0.237 |
Positive | 66 | 61.1% | 42 | 38.9% | 127 | 75.1% | 42 | 24.9% |
Association of p-P38 with DNA repair markers
Variable | nuclear p-P38 | |||||
---|---|---|---|---|---|---|
negative / low | high |
p
| ||||
nuclear BRCA1 | negative | 402 | (85.4%) | 69 | (14.6%) |
< 0.001
*
|
positive | 365 | (63.6%) | 209 | (36.4%) | ||
nuclear BRCA2 | negative | 540 | (72.0%) | 210 | (28.0%) | 0.393 |
positive | 44 | (66.7%) | 22 | (33.3%) | ||
PARP1 | negative | 346 | (75.4%) | 113 | (24.6%) | 0.074 |
positive | 373 | (70.1%) | 159 | (29.9%) | ||
cleaved PARP1 | negative | 114 | (85.7%) | 19 | (14.3%) |
< 0.001
*
|
positive | 563 | (71.5%) | 224 | (28.5%) | ||
nuclear RAD51 | negative | 327 | (82.4%) | 70 | (17.6%) |
< 0.001
*
|
positive | 184 | (62.8%) | 109 | (37.2%) | ||
TP53 | negative | 636 | (70.6%) | 265 | (29.4%) | 0.337 |
positive | 268 | (73.4%) | 97 | (26.6%) |
Overall survival analysis based on clinicopathological characteristics, hormone receptor status and P38 expression
Characteristic | Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|---|
HR | 95% CI |
p
| HR | 95% CI |
p
| ||
p-P38 | low |
reference
|
reference
| ||||
high | 0.735 | 0.617–0.875 |
0.001
*
| 0.796 | 0.662–0.957 |
0.015
*
| |
NPI | good/medium |
reference
|
reference
| ||||
poor | 2.465 | 2.054–2.959 |
< 0.001
*
| 2.120 | 1.731–2.596 |
< 0.001
*
| |
VI | negative or suspected |
reference
|
reference
| ||||
positive (definite) | 1.436 | 1.225–1.683 |
< 0.001
*
| 1.161 | 0.973–1.384 | 0.097 | |
ER | negative |
reference
|
n/a
| ||||
positive | 0.917 | 0.764–1.100 | 0.350 | ||||
PR | negative |
reference
|
reference
| ||||
positive | 0.711 | 0.607–0.832 |
< 0.001
*
| 0.830 | 0.703–0.980 |
0.028
*
| |
HER2 | negative |
reference
|
reference
| ||||
positive | 1.722 | 1.393–2.128 |
< 0.001
*
| 1.486 | 1.191–1.856 |
< 0.001
*
|